"目录号: HY-14806
Metabolic Enzyme/Protease-
Teneligliptin 是一种有效的DPP-4抑制剂，竞争性抑制人血浆，大鼠血浆和人重组DPP-4，IC50约为 1 nM。
Dipeptidyl Peptidase
相关产品
Sitagliptin-Talabostat mesylate-Saxagliptin-Linagliptin-Omarigliptin-Anagliptin-Vildagliptin-Trelagliptin-Alogliptin Benzoate-DBPR108-Teneligliptin hydrobromide-UAMC00039 dihydrochloride-Dutogliptin-Gosogliptin-Prodipine hydrochloride-
生物活性
Description
Teneligliptin is a potent chemotype prolylthiazolidine-basedDPP-4inhibitor, which competitively inhibits human plasma, rat plasma, and human recombinant DPP-4 in vitro, withIC50s of approximately 1 nM.
IC50& Target
IC50: 1 nM (DPP4)[1]
In Vitro
Teneligliptin inhibits all these DPP-4 enzymes in a concentration-dependent manner. The IC50s of Teneligliptin for rhDPP-4, human plasma, and rat plasma are 0.889, 1.75, and 1.35 nM, respectively. A study of enzyme inhibition kinetics is conducted for Teneligliptin using Gly-Pro-MCA as the substrate and rhDPP-4 as the enzyme source. Plots based on the Michaelis-Menten equation reveals that Teneligliptin inhibits DPP-4 in a substrate-competitivemanner; the residual sum of squares for competitive and non-competitive models is 0.162 and 0.192, respectively. Ki, Km, and Vmaxvalues are 0.406 nM, 24 μM, and 6.06 nmol/min, respectively. Teneligliptin inhibits the degradation of GLP-1(7-36)amide with an IC50of 2.92 nM[1].
In Vivo
Oral administration of Teneligliptin in Wistar rats results in the inhibition of plasma DPP-4 with an ED50of 0.41 mg/kg. Plasma DPP-4 inhibition is sustained even at 24 h after administration of Teneligliptin. An oral carbohydrate-loading test in Zucker fatty rats shows that Teneligliptin at ≥0.1 mg/kg increases the maximum increase in plasmaglucagon-like peptide-1 and insulin levels, and reduces glucose excursions. This effect is observed over 12 h after a dose of 1 mg/kg. An oral fat-loading test in Zucker fatty rats also shows that Teneligliptin at 1 mg/kg reduces triglyceride and free fatty acid excursions. In Zucker fatty rats, repeated administration of Teneligliptin for two weeks reduces glucose excursions in the oral carbohydrate-loading test and decreased the plasma levels of triglycerides and free fatty acids under non-fasting conditions. Oral administration of Teneligliptin inhibits plasma DPP-4 in rats in a dose-dependent manner. The ED50value for Teneligliptin is calculated to be 0.41 mg/kg, while those for Sitagliptin and Vildagliptin, 27.3 and 12.8 mg/kg, respectively[1].Teneligliptin improves the histopathological appearance of the liver and decreases intrahepatic triglyceride levels in an NAFLD model mouse, which is associated with downregulation of hepatic lipogenesis-related genes due to AMPK activation[2].
Clinical Trial
NCT02354222
Mitsubishi Tanabe Pharma Corporation
Type 2 Diabetes Mellitus
January 2015
Phase 3
NCT03011177
Handok Pharmaceuticals Co., Ltd.
Type2 Diabetes Mellitus
January 2017
Phase 4
NCT02449330
National Cerebral and Cardiovascular Center
Diabetes Mellitus, Type 2
June 2015
Phase 4
NCT02081599
Mitsubishi Tanabe Pharma Corporation
Type 2 Diabetes Mellitus
January 2014
Phase 4
NCT02354235
Mitsubishi Tanabe Pharma Corporation
Type 2 Diabetes Mellitus
January 2015
Phase 3
NCT02220907
Mitsubishi Tanabe Pharma Corporation
Type 2 Diabetes Mellitus
August 2014
Phase 3
NCT02916706
Mitsubishi Tanabe Pharma Corporation
Type 2 Diabetes Mellitus
September 2016
Phase 3
NCT02314637
Mitsubishi Tanabe Pharma Corporation
Type 2 Diabetes Mellitus
August 2009
Phase 3
NCT02567994
Handok Pharmaceuticals Co., Ltd.
Type 2 Diabetes Mellitus
January 2015
Phase 3
NCT02924064
Mitsubishi Tanabe Pharma Corporation
Type 2 Diabetes Mellitus
September 2016
Phase 3
NCT03009513
Handok Pharmaceuticals Co., Ltd.
Diabetes Mellitus
January 2017
Phase 1
NCT00998881
Mitsubishi Tanabe Pharma Corporation
Type 2 Diabetes Mellitus
September 2009
Phase 3
NCT02512523
Handok Pharmaceuticals Co., Ltd.
Type 2 Diabetes Mellitus
August 2015
Phase 4
NCT00628212
Mitsubishi Tanabe Pharma Corporation
Type 2 Diabetes
January 2008
Phase 2
NCT00974090
Mitsubishi Tanabe Pharma Corporation
Type 2 Diabetes Mellitus
September 2009
Phase 3
NCT01026194
Mitsubishi Tanabe Pharma Corporation
Type 2 Diabetes Mellitus
December 2009
Phase 3
NCT01301833
Mitsubishi Tanabe Pharma Corporation
Type 2 Diabetes Mellitus
February 2011
Phase 3
View MoreCollapse
References
[1].Fukuda-Tsuru S, et al. A novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor, teneligliptin, improves postprandial hyperglycemia and dyslipidemia after single and repeated administrations. Eur J Pharmacol. 2012 Dec 5;696(1-3):194-202.
[2].Ideta T, et al. The Dipeptidyl Peptidase-4 Inhibitor Teneligliptin Attenuates Hepatic Lipogenesis via AMPK Activation in Non-Alcoholic Fatty Liver Disease Model Mice. Int J Mol Sci. 2015 Dec 8;16(12):29207-18.